(1061) Long-Term Changes in Renal Function After Implantation of Left Ventricular Assist Device and Differences by Type of Devices from Japanese Registry for Mechanical Assisted Circulatory Support (J-MACS)

PurposeSevere heart failure patients often have renal dysfunction (RD) due to low cardiac output. It has been reported that RD improves after the implantation of left ventricular assist device (LVAD), however, it is unclear whether there are differences of improvement on renal function among type of devices.MethodsThis study was a retrospective observational cohort study using Japanese registry for mechanical assisted circulatory support (J-MACS). The study included 1,353 patients implanted with LVAD between 2010 and 2019. We investigated changes in renal function of each different type of devices over 2 years.ResultsThe patients’ mean age at LVAD implantation was 44 ± 14 years; 1,005 (74%) were male. Regarding to device models, HeartMate II (axial flow type) was used in 632 (47%), Jarvik (axial flow type) in 198 (15%) and EVAHEART (centrifugal type) in 195 (14%) patients. Mean estimated glomerular filtration rate (eGFR) at LVAD implantation was 77 ± 47 ml/min/1.73m2; 545 (40 %) patients had RD (eGFR < 60 ml/min/1.73m2). Renal function after LVAD implantation was significantly improved up to 6 months post-implantation compared to pre-implantation, but thereafter came down to equivalent to that in pre-implantation (Figure). All three of device models had significantly improved renal function at 1 month post-implantation compared to pre-implantation. EVAHEAERT improved significantly up to 6 months, HeartMate II improved up to 3 months, and Jarvik only significantly improved up to 1 month after implantation.ConclusionRenal function improved early after LVAD implantation, but gradually declined in most patients over 2 years. Changes in renal function after LVAD implantation were different in each device. Severe heart failure patients often have renal dysfunction (RD) due to low cardiac output. It has been reported that RD improves after the implantation of left ventricular assist device (LVAD), however, it is unclear whether there are differences of improvement on renal function among type of devices. This study was a retrospective observational cohort study using Japanese registry for mechanical assisted circulatory support (J-MACS). The study included 1,353 patients implanted with LVAD between 2010 and 2019. We investigated changes in renal function of each different type of devices over 2 years. The patients’ mean age at LVAD implantation was 44 ± 14 years; 1,005 (74%) were male. Regarding to device models, HeartMate II (axial flow type) was used in 632 (47%), Jarvik (axial flow type) in 198 (15%) and EVAHEART (centrifugal type) in 195 (14%) patients. Mean estimated glomerular filtration rate (eGFR) at LVAD implantation was 77 ± 47 ml/min/1.73m2; 545 (40 %) patients had RD (eGFR < 60 ml/min/1.73m2). Renal function after LVAD implantation was significantly improved up to 6 months post-implantation compared to pre-implantation, but thereafter came down to equivalent to that in pre-implantation (Figure). All three of device models had significantly improved renal function at 1 month post-implantation compared to pre-implantation. EVAHEAERT improved significantly up to 6 months, HeartMate II improved up to 3 months, and Jarvik only significantly improved up to 1 month after implantation. Renal function improved early after LVAD implantation, but gradually declined in most patients over 2 years. Changes in renal function after LVAD implantation were different in each device.